Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Leukemia
E K MaiHartmut M Goldschmidt

Abstract

We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly diagnosed, transplant-eligible multiple myeloma patients. VCD was found to be non-inferior to PAd with respect to ⩾VGPR rates (37.0 versus 34.3%, P=0.001). The rates of progressive disease (PD) were 0.4% (VCD) versus 4.8% (PAd; P=0.003). In the PAd arm, 11 of 12 patients with PD had either renal impairment (creatinine ⩾2 mg/dl) at diagnosis or the cytogenetic abnormality gain 1q21, whereas no PD was observed in these subgroups in the VCD arm. Leukocytopenia/neutropenia (⩾3°) occurred more frequently in the VCD arm (35.2% versus 11.3%, P<0.001). Neuropathy rates (⩾2°) were higher in the PAd group (14.9 versus 8.4%, P=0.03). Serious adverse events, both overall and those related to thromboembolic events, were higher in the PAd group (32.7 versus 24.0%, P=0.04 and 2.8 versus 0.4%, P=0.04). Stem cell collection was not impeded by VCD. VCD is as effective as PAd in terms of achieving ⩾VGPR rates with fewer PD and has a favorable toxicity profile. Therefore, VCD is preferable to PAd as induct...Continue Reading

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Oct 3, 2008·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Sabrina RavagliaAlfredo Costa
Jul 30, 2009·Blood·Jean-Luc HarousseauHerve Avet-Loiseau
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher A Chanan-Khan, Sergio Giralt
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigJean-Luc Harousseau
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz

❮ Previous
Next ❯

Citations

Dec 17, 2015·The Lancet Oncology·Christof Scheid
Nov 26, 2015·The Lancet Oncology·Philip L McCarthy, Sarah A Holstein
Nov 5, 2016·Journal of Cancer Research and Clinical Oncology·Nils WinkelmannSebastian Scholl
Feb 17, 2017·Journal of Internal Medicine·O Landgren, K Iskander
Mar 10, 2017·Blood·Michel Delforge, Heinz Ludwig
Apr 21, 2018·British Journal of Haematology·Lalit Kumar, Prasanth Ganesan
Oct 7, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Elizabeth H PhillipsAshutosh D Wechalekar
Dec 3, 2017·Cancer Metastasis Reviews·Sara GandolfiPaul G Richardson
Nov 15, 2018·Expert Review of Proteomics·Thomas A Guerrero-GarciaPaul G Richardson
Oct 20, 2018·Expert Review of Hematology·Agne PanerEdward N Libby
Jan 17, 2019·International Journal of Cancer. Journal International Du Cancer·Evangelos TerposMeletios A Dimopoulos
Apr 2, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph MikhaelTom Martin
Jan 13, 2016·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Jochen Taupitz, Marie Schreiber
Jul 28, 2017·Blood·Philippe Moreau
Sep 9, 2017·Current Opinion in Nephrology and Hypertension·Colin A HutchisonPeter Mollee
Apr 16, 2020·Expert Review of Hematology·Mehmet H Kocoglu, Ashraf Z Badros
Jun 24, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank BridouxUNKNOWN MYRE study group
Mar 17, 2016·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Silke HellmichMichael Hallek
Jun 20, 2020·European Journal of Haematology·Fredrik Schjesvold
Dec 22, 2017·Expert Opinion on Pharmacotherapy·Massimo OffidaniSilvia Gentili
Aug 14, 2018·Japanese Journal of Clinical Oncology·Kiyoshi Okazuka, Tadao Ishida
Jul 21, 2020·Leukemia·Elias K MaiUNKNOWN German-speaking Myeloma Multicenter Group (GMMG)
Jul 27, 2015·Toxics·Cristina Meregalli
May 8, 2018·Journal of Nephrology·Insara Jaffer SathickNelson Leung
Jul 1, 2018·Leukemia·Elias K MaiUNKNOWN German-speaking Myeloma Multicenter Group (GMMG)
Dec 4, 2016·Hematology·Angela Dispenzieri
Nov 25, 2018·Annals of Hematology·Hartmut GoldschmidtLaurent Garderet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.